Orchid Orthopedic Solutions Selects CEBOS Quality Management System to Support Rapid Growth and Meet Compliance
CEBOS Enables Medical Device Manufacturer to Integrate Quality Management Throughout its Manufacturing Processes
SANTA BARBARA, CA — April 15, 2014 — CEBOS, a division of QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB) and a leading provider of enterprise quality management software (EQMS) to global companies, announced that Orchid Orthopedic Solutions (Orchid) selected CEBOS MQ1 Elements to automate its quality management system and ensure compliance with industry-specific quality standards.
Orchid, a global leader of medical device outsourcing services, provides expertise from design and development through finished goods manufacturing to clients in more than 20 countries. One of its goals is to collaborate with customers and suppliers to provide reliable results, develop superior solutions and continually enhance its business processes to serve as the best total supply chain value in the industry. To support its rapid growth and align its operations to strategic goals, Orchid realized it needed an enterprise wide quality management solution to enhance collaboration, improve the total quality of each product delivered and achieve operational excellence.
Orchid conducted a comprehensive analysis of EQMS solutions in the marketplace evaluating functionality, technology development platforms, technology delivery models, as well as industries and geographies served. “We evaluated the top EQMS solutions providers,” said Bill Ditty, Orchid’s vice president of quality. “The CEBOS MQ1 Elements Life Sciences Solution offered the breadth of functionality we require for automation, compliance and integration coupled with in-depth, industry-specific expertise. In addition to meeting our technical requirements, and of critical importance to us, is it’s simple to use.”
CEBOS MQ1 technology is a suite of EQMS solutions that allows life sciences manufacturers to automate quality throughout their business. From the plant floor to the boardroom, CEBOS enables organizations to streamline and automate compliance processes to meet the most stringent standards and governmental regulations, such as International Organization for Standardization (ISO) and Federal Drug Administration (FDA) regulations. MQ1 Elements Life Sciences Solution is a completely automated, integrated, quality management system geared to the requirements of ISO, FDA and good manufacturing practices and more. Functionality includes configurable forms and workflows, electronic signatures, audit trails and validation scripts. The software significantly reduces the time required to complete and maintain regulatory compliance providing staff with visibility to business processes, tasks and timing.
“Today’s leading life sciences organizations like Orchid want to ensure they are aligning their processes to strategic goals to produce and deliver innovative, safe and effective healthcare products,” said CEBOS President Bob Herdoiza. “CEBOS is focused on providing customers with a quality management solution that continually exceeds ever-changing, evolving requirements while making the compliance process easy.”
About CEBOS – Effective Enterprise Compliance
CEBOS, a division of QAD Inc., (NASDAQ: QADA) (NASDAQ: QADB), provides a suite of enterprise quality and environmental, health and safety management software solutions. CEBOS solutions are designed to simplify ever-changing management compliance requirements including: ISO, TS, FDA, AS, OHSAS, cGxP. CEBOS solutions provide a wide range of functionality including: APQP/PPAP, Audit, Corrective Action (CAPA), Nonconformance, Document Control, Gauge Calibration, Equipment Maintenance, Shop Floor Inspection and Statistical Process Control (SPC), Supplier Management, Project and Program Management, and Training Tracking. CEBOS software enables customers in any industry to meet their goals of managing compliance and becoming more Effective Enterprises. For more information about CEBOS, visit www.cebos.com/ or email email@example.com
Orchid is a worldwide leader in contract design and manufacturing for the orthopedic and medical device markets. Our goal is to be the leader in contract design and manufacturing by compressing time to market, providing new technologies and being the best total supply-chain value. We provide expertise in design and development, quality and regulatory support, implant manufacture, advanced machining, plastics technology, instrument manufacture, implant coatings and surface treatment and packaging services. With 13 world class facilities located around the globe, Orchid provides the products and services that improve the lives of patients worldwide. For more information about Orchid, visit the company’s website at www.orchid-ortho.com.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
For additional information, contact:
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, “would”, “might”, “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for its fiscal year ended January 31, 2014, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.